Multiple Medication Supply Agreement

This Supply Agreement (the "Agreement") is made and entered into as of October 3, 2024, by and between:

Merck & Co., Inc., a corporation organized and existing under the laws of the State of New Jersey, USA, with its principal place of business located at One Merck Drive, Whitehouse Station, NJ 08889-0100 (hereinafter referred to as "Merck"); and

Global Pharma Distributors, a drug distribution company with its principal places of business in both the US (123 Market Street, New York, NY 10001) and Europe (456 Health Avenue, Berlin, Germany 10115) (hereinafter referred to as "Distributor").

WHEREAS:

- Merck is engaged in the development, manufacturing, and sale of medicines, including the medicines subject to this Agreement;
- Distributor operates a drug distribution business in the US and Europe and requires a consistent supply of medicines for distribution to healthcare providers and retail pharmacies;

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the parties agree as follows:

1. Supply of Medicines

Merck agrees to sell and deliver to Distributor, and Distributor agrees to purchase from Merck, the following medications (the "Products"):

Product Name Unit Price (USD) Number of Units per Batch Price per Batch (USD)				
Distribution Regions				
CardiGuard - Hypertension Medicat	ion \$75	10,000	\$750,000	1
US, Europe				
FluGuard - Influenza Vaccine	\$120	5,000	\$600,000	US,
Europe				
DiabeSure - Diabetes Treatment	\$95	8,000	\$760,000	US
only				
NeuroMax - Neuropathy Treatment	\$150	6,000	\$900,000	1
Europe only				
ImmunoSafe - Immune Booster	\$50	15,000	\$750,000	US,
Europe				

2. Contract Price

The price for the Products shall be as listed in the table above. All prices are exclusive of applicable taxes, duties, or other charges unless otherwise specified. Invoices will be issued by Merck and payable within 30 days of the delivery of each batch to Distributor.

3. Term and Delivery Timeline

This Agreement shall commence on October 3, 2024, and continue for a period of two (2) years, expiring on October 3, 2026, unless terminated earlier in accordance with the terms of this Agreement.

- Delivery Schedule:

- Deliveries of each Product shall occur quarterly, with the first delivery starting on November 1, 2024.

4. Quality and Inspection

Merck warrants that the Products delivered shall:

- Conform to the specifications provided in Attachment A.
- Be free from defects in materials and workmanship.
- Comply with all applicable regulatory requirements.

Distributor reserves the right to inspect and test the Products upon delivery. If the Products fail to meet the agreed specifications, Distributor may, at its discretion:

- Reject the delivery and request replacement within 30 days.
- Adjust the purchase price or request a refund.

5. Payment Terms

- Distributor shall make payment via wire transfer within 30 days of the receipt of each batch of the Products and the corresponding invoice from Merck.
- Late payments shall bear interest at a rate of 1.5% per month on the outstanding balance.

6. Termination

Either party may terminate this Agreement upon 60 days' written notice to the other party. Grounds for immediate termination by Merck include:

- Failure to meet payment schedules for two consecutive months.
- Distributor's breach of any material term of this Agreement not cured within 30 days of written notice.

7. Confidentiality

Both parties agree to maintain the confidentiality of any proprietary or sensitive information

exchanged during the performance of this Agreement. This obligation shall survive the termination of

this Agreement for a period of five (5) years.

8. Force Majeure

Neither party shall be liable for any delay or failure to perform due to causes beyond their

reasonable control, including but not limited to acts of God, government regulations, war, strikes,

and natural disasters. The affected party shall notify the other in writing of any such event within 10

days of its occurrence.

9. Governing Law

This Agreement shall be governed by and construed in accordance with the laws of the State of

New Jersey, USA, without regard to its conflict of law provisions.

10. Entire Agreement

This Agreement constitutes the entire understanding between the parties with respect to the subject

matter herein and supersedes all prior discussions, agreements, or understandings of any kind.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their

duly authorized representatives as of the date first written above.

Merck & Co., Inc.

By:

Name: John Doe

Title: Vice President of Procurement

Date: October 3, 2024

Global Pharma Distributors

By: _____

Name: Sarah White

Title: Chief Operating Officer

Date: October 3, 2024